MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us

NRG-BN003

Trial

Clinical Trial Title

NRG-BN003

Trial Status

Open to Enrollment

Start Date

July 24, 2017

Location

Trial Type

Cancer (Oncology)

Specific Condition

Grade II Meningioma

Description

 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Eligibility Criteria

  • Histologically confirmed diagnosis of WHO grade II meningioma confirmed by central pathology review
  • Age ≥ 18
  • Post-operative Zubrod Performance Status 0-1 within 60 days
  • History/physical examination, including neurologic examination within 60 days
  • If the patient is a woman is of childbearing potential, a serum pregnancy test, obtained within 14 days
     

Ineligibility Criteria

  • Optic nerve sheath meningioma, spinal or other extracranial meningioma, multiple meningiomas, hemangiopericytoma
  • Definitive evidence of metastatic meningioma
  • Prior invasive malignancy unless disease free for a minimum of 3 years
  • Previous radiotherapy to the scalp, cranium, brain, or skull base and radiation-induced meningiomas
  • Inability to undergo MRI with and without contrast

Please contact Legacy Oncology Research for additional study inclusion/exclusion information

 

IRB Number

Central IRB

Principal Investigator Name

Andrew Kee, MD

Contact Name

Oncology Clinical Research

Phone

503-413-8199

Contact Fax

503-413-6920

Contact E-Mail

oncologyresearch@lhs.org

Last Updated: Thursday, December 28, 2017 12:53:16 PM